Cost of Goods Sold (Annual)

Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.

Harmony Biosciences Holdings, Inc. (HRMY) had Cost of Goods Sold of $198.34M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$868.45M
Net Income	$158.69M
Cost of Goods Sold	$198.34M
Gross Profit	$670.11M
Operating Expenses	$659.98M
Operating Income	$208.47M
Non-Operating Income/Expense	$6.59M
Pre-Tax Income	$215.06M
Normalized Pre-Tax Income	$215.06M
Income after Taxes	$158.69M
Income from Continuous Operations	$158.69M
Consolidated Net Income/Loss	$158.69M
Normalized Income after Taxes	$158.69M
EBIT	$208.47M
EBITDA	$232.93M
Weighted-Average Shares Outstanding (Basic)	57.49M
Weighted-Average Shares Outstanding (Diluted)	58.54M
Earnings per Share (EPS) (Basic)	$2.76
Earnings per Share (EPS) (Diluted)	$2.71
Balance Sheet Financials
Current Assets	$907.01M
Property, Plant, and Equipment	--
Long-Term Assets	$364.62M
Total Assets	$1.27B
Current Liabilities	$252.13M
Long-Term Debt	$143.66M
Long-Term Liabilities	$149.28M
Total Liabilities	$401.41M
Common Equity	$870.22M
Tangible Shareholders Equity	$780.80M
Shareholders Equity	$870.22M
Common Shares Outstanding	57.73M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$348.20M
Cash Flow from Investing Activities	$-39.65M
Cash Flow from Financial Activities	$-9.05M
Beginning Cash	$453.27M
End Cash	$752.77M
Increase/Decrease in Cash	$299.50M
Stock-Based Compensation	$44.90M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.60
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.14
Debt to Equity Ratio	0.19
Gross Margin	77.16%
Operating Margin	24.00%
EBIT Margin	24.00%
EBITDA Margin	26.82%
Pre-Tax Profit Margin	24.76%
Profit Margin	18.27%
Free Cash Flow	$347.89M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.68
Inventory Turnover	37.02
Receiveable Turnover	8.97
Days Sales in Receivables	40.68
Return on Equity	18.24%
Return on Tangible Equity	20.32%
Return on Assets	12.48%
Return on Investments	15.65%
Book Value Per Share	$15.07
Free Cash Flow per Share	$5.94
Operating Cash Flow per Share	$5.95

Data from Zacks Investment Research, Inc.